Two protein kinases, called DCLK1 and STK33, may serve as candidates for a molecular targeted therapy of idiopathic pulmonary…
Articles by Margarida Maia, PhD
The more monocyte immune cells that circulate in a person’s bloodstream, the greater the odds that lung abnormalities, such as…
Algernon Pharmaceuticals hit the full enrollment of 20 patients with idiopathic pulmonary fibrosis (IPF) in its Phase 2…
Fibrosis or scarring in the lungs may blunt the ability of the body’s immune cells to fight off an infection…
Pulmonary rehabilitation is as effective a treatment for idiopathic pulmonary fibrosis (IPF) as it is for chronic obstructive pulmonary disease…
A signaling molecule called interleukin 35 (IL-35) is at unusually high levels in lung tissues from mice and in people…
A protein called RAGE may be a useful biomarker for the diagnosis and prognosis of idiopathic pulmonary fibrosis (IPF),…
People with idiopathic pulmonary fibrosis (IPF) have an eight times higher risk of mortality during hospitalizations or within three…
Certain genetic variants appear to lead to better survival in people with idiopathic pulmonary fibrosis (IPF) who are on…
Esbriet (pirfenidone) appears to slow the progression of idiopathic pulmonary fibrosis (IPF) regardless of the presence of autoantibodies,…